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See Article, pages 948–955A key role of chronic hepatocyte damage, leading to liver inﬂam-
mation, ﬁbrosis, and eventually cirrhosis, in the development of
hepatocellular carcinoma (HCC) has been long established.
Although the chronic stimulation of liver regeneration is one of
the main contributors to HCC development, the accompayning
inﬂammation has also been established as a pivotal component
[1,2]. Less is known about the role of ongoing inﬂammation with
regard to disease progression once HCC has developed. A ﬁrst
hint of the relevance of the inﬂammatory response in tumour
progression came from a seminal study from Budhu et al., linking
a pro-inﬂammatory peritumoural cytokine milieu with the prog-
nosis and metastatic spread of HCC [3]. There is increasing evi-
dence that the inﬂammatory milieu, by virtue of both its
soluble signals, cellular inﬁltrates, and physical properties, may
alter the behaviour of HCC [4–6].
In the study published in this issue by Kuang et al., the role of
inﬁltrating neutrophils in the stroma of HCC, in the perspective of
clinical and experimental disease progression, has been charac-
terized [7]. The authors found an enrichment of neutrophils pre-
dominantly in the peritumoral stroma surrounding the cancer
cell nests at the interface between tumour and non-tumour tis-
sue and identiﬁed a high neutrophil inﬁltration as a powerful
predictor of disease progression and poor overall survival after
HCC resection. Interestingly, the neutrophil numbers, neither
within the tumour nor in the adjacent non-tumour liver, proved
to be of prognostic value. Neutrophil numbers correlated with
IL-17 positive lymphocyte numbers – a subset of CD4+ T-cells
previously identiﬁed by the same group as important immune
modulators of HCC – in the same region of the tumour. Although
IL-17 did not seem to have a direct effect on neutrophil recruit-
ment, it was able to stimulate epithelial CXC chemokine produc-
tion, thereby attracting neutrophils to the stroma and prolonging
neutrophil survival. The tumour cell activated neutrophils were
identiﬁed as the main source of MMP-9 production, which was
linked to angiogenesis in vitro and correlated with vessel densityJournal of Hepatology 20
qDOI of original article: 10.1016/j.jhep.2010.08.041.
⇑ Corresponding author. Address: I. Medical Department, University Medical
Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. Tel.:
+49 (0) 40 741050054; fax: +49 (0) 40 741059092.
E-mail addresses: jschrade@uke.uni-hamburg.de, jschrade@uke.de (J. Schrader).in clinical HCC samples. Importantly, depletion of neutrophils, by
Gr1-targeting antibody treatment of mice, delayed HCC xenograft
development and impaired tumour angiogenesis.
A poor predictive value of an elevated neutrophil-to-lympho-
cyte ratio in peripheral blood has been long established in many
tumours, including HCC [8]. It is only recently that intratumoural
neutrophils have been associated with higher recurrence rates
and decreased survival in patients with renal cancer and hepato-
cellular carcinoma after curative resection [9,10]. The present
study extends these ﬁndings with regard to the precise localiza-
tion of the neutrophil inﬁltration in the peritumoral stroma [7]. It
is in this area where the main interaction between the tumour
and the surrounding tissue will take place. This is the predomi-
nant place for both angiogenesis and cancer cell invasion, thereby
fostering tumour progression and metastatic spread. The neutro-
phils can stimulate angiogenesis by releasing MMP9 and enhance
invasion of tumour cells by production of chemoattractant
growth factors like the hepatocyte growth factor and others
[11,12]. In addition, neutrophils can contribute to or prevent
the cytotoxic immune response against tumour cells by interact-
ing with CD8+ cytotoxic T-cells, depending on their activation sta-
tus [13]. Whether a polarized N1 or N2 phenotype of neutrophils
– as proposed by Fridlender et al. in analogy to macrophage phe-
notypes [13] – exists in HCC, needs to be further clariﬁed, but
clearly the local cytokine environment including TGFb could be
responsible for shifting phenotypes. It would be most interesting
to further characterize the inﬁltrating neutrophil phenotype in
HCC and link this to disease progression and outcome.
The peritumoral stroma surrounding the cancer cell nest at
the tumour edge, attracting neutrophils, macrophages, and lym-
phocytes, becomes the ‘‘battle ground’’ for the interaction of
the tumour with the immune system [4,5,7]. Given the additional
presence of activated myoﬁbroblasts in this area, all components
of the classic wound healing response are present, reiterating the
phrase of ‘‘tumours are wounds that do not heal’’ coined by Dvo-
rak [14]. The physiological role of wound healing is to combat
infection, close a tissue defect by inital ﬁbrosis, recruit new blood
vessels, and re-establish tissue integrity [15]. With regard to
tumour-associated inﬂammation, angiogenesis and ﬁbrosis are
common outcomes, but the re-establishment of tissue integrity
fails due to the persistence of the causative agent, the ‘‘abberant’’11 vol. 54 j 853–855
Editorial
tumour cells. The recruitment of inﬂammatory and stroma cells
to sites of tissue repair and infection is a complex process
involving cytokines, chemokines, and direct cell–cell interactions.
Similarly, the establishment of the inﬂammatory tumour envi-
ronment is growing a complex tissue and involves an extensive
cross-talk between tumour cells and inﬁltrating cells. Kuang
et al. deﬁne a communication circuit between Th17 lymphocytes,
epithelial tumour cells, neutrophils, and feedback via tumour
cells to endothelial cells, leading to angiogenesis [7]. Certainly,
other communication circuits will also exist and have, for exam-
ple, been established for a cross-talk between tumour cells, acti-
vated macrophages, and Th17 cells [4].
A longstanding area of debate is whether the tumour microen-
vironment in general is pro- or anti-inﬂammatory and whether
the inﬁltrating immune cells promote tumour growth or act as
immune-surveillance to combat tumour progression. The answer
to these questions will not be easy to deﬁne. Currently, our
knowledge would suggest a ‘‘bit of both’’ answer. The tumours
utilize a pro-inﬂammatory environment with the aim of tissue
re-modelling, angiogenesis, and stimulation of migration and
invasion [16]. On the other hand, they induce powerful mecha-
nisms to prevent the immune attack of tumour cells by inducing
a suppressive phenotype in macrophages and recruiting regula-
tory T cells, thereby preventing cytotoxic lymphocyte function
[17]. This paradoxical state of ‘‘a bit of both worlds’’ might be sim-
ilar to a later phase in the wound healing response, where a cer-
tain pro-inﬂammatory action is still needed to re-organize and
repair the tissue but also immune suppression is needed to cool
down the immune response to prevent further tissue damage
and allow epithelial cells to resume normal function [15]. Exploit-
ing the inﬂammatory response to combat cancer would require a
shift of the whole immune response rather than interfering with
single cytokines or immune cells. A skewing of the inﬂammatory
reaction towards either end of the wound healing response,
namely acute inﬂammation associated with tissue damage or
complete resolution of the inﬂammatory reaction, would be the
aim of this intervention. Indeed, clinical data show that, on the
one hand, a cytokine proﬁle linked with acute inﬂammation
(e.g. TNFa, IFNc) and inﬁltrating cytotoxic lymphocytes can pre-
vent tumour progression and, on the other hand, non-inﬂamma-
tory tumours have in general a more benign course [3,7,16,17].
Conversely, it may be that speciﬁc HCCs develop and spread
highly effectively in the presence of signiﬁcant inﬂammation
and ﬁbrosis. Within this context, the evolution of cancer would
favour the development of one which responded positively or
elicited a growth/survival advantage from an inﬂammatory
milieu. Thus ultimately, it may prove that reducing inﬂammation
is an important approach to certain tumours.
Are there similarities between the chronic liver inﬂammation
leading to ﬁbrosis and the tumour-associated inﬂammation in
HCC? Certainly, activated macrophages and myoﬁbroblasts are
key-players of both ﬁbrosis development and HCC progression.
In analogy to the present study by Kuang et al., Th17 cells have
recently been found to also contribute to the inﬂammatory reac-
tion in alcoholic hepatitis [18]. In this setting, these cells are able
to recruit neutrophils via chemokine induction in activated stel-
late cells. Although in this context neutrophils contribute to the
ongoing inﬂammation and liver damage, their role in liver ﬁbrosis
is not yet clear, as they also can contribute to the resolution of
ﬁbrosis after the insulting stimulus is gone [19]. Further studies
might clarify this issue andmay bring the proof that different neu-854 Journal of Hepatology 201trophil subtypes are responsible for these apparently opposing
outcomes. One interesting question would be whether the
tumour-associated inﬂammation is a mere extension of the
chronic liver inﬂammation which leads to tumour formation, or
whether the tumours themselves recruit and modulate their
own inﬂammatory environment. Results from xenograft studies
showing immune cell recruitment might favour the latter. On
the other hand, clinical data show that the activity of liver inﬂam-
mation in the non-tumourous liver per se is a poor prognostic fac-
tor for survival after HCC resection, arguing for the former [3].
Interestingly, the present study suggests that the edge of the
tumour represents an important interface for both inﬂammatory
environments. Further studies will have to clarify the differences
and similarities of the inﬂammatory environments and might
help to identify pro-tumourigenic and anti-tumourigenic milieus.Conﬂict of interest
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